血清COX-2对非小细胞肺癌诊断的临床意义

The clinical significance of serum levels of COX-2 in diagnosis of non-small cell lung cancer

目的综合评价血清环氧化酶-2(COX-2)与其它肿瘤标记物对非小细胞肺癌诊断及预测疾病状态的临床意义。方法利用ELISA方法和快速发光免疫分析法分别测定70例非小细胞肺癌患者、22例良性肺疾病患者以及16例健康人体血清中COX-2、CEA、CA125和CA19-9的水平。结果非小细胞肺癌患者血清中COX-2、CEA、CA125和CA19-9的水平均显著高于良性肺疾病组和健康组(p<0.01)。另外,COX-2的水平随肿瘤体积增大、淋巴结转移以及临床分期进展而显著升高(p<0.01)。结论血清COX-2与CEA、CA125和CA19-9对非小细胞肺癌诊断都具有一定的临床价值,血清COX-2还是一项预测非小细胞肺癌侵袭、转移等疾病状态的良好指标。

Objective To evaluate the application of COX-2 and other tumor markers in serum in diagnosing non-small cell lung cancer （NSCLC） and their correlation with the clinical stage of NSCLC. Methods Using the ELISA method and tumor markers protein chip, the serum levels of COX-2, CEA, CA125 and CA 19-9 in 73 cases of NSCLC, 21 cases of benign pulmonary disease and 16 cases of normal controls were measured and compared among the three groups of the cases. Results The concentrations of serum COX-2, CEA, CA125 and CA19-9 in the patients with NSCLC were significantly higher than those in the group with benign lung disease and in the control group （p 〈 0. 01）. The levels of COX-2 remarkably went up in NSCLC patients with increase in tumor size, lymph node metastasis and clinical stage development （p 〈 0. 01）. Conclusion serum levels of COX-2, CEA, CA125 and CA19-9 were much valuable in diagnosis of NSCLC. Furthermore, the serum COX-2 would also be a good marker for the invasion, metastasis and status of NSCLC.